Clavis, DNO, East Capital, Kone, Vestas: Nordic Stock Preview

The following companies’ shares may have unusual price changes in Nordic trading. Stock symbols are in parentheses and share prices are from the previous close.

The Stoxx Nordic 30 Index, the benchmark measure for the region, fell 0.4 percent to 7,080.27 in Stockholm, paring the 1 percent gain on Nov. 9.

The OMX Stockholm 30 Index slipped 0.6 percent. Norway’s OBX Index retreated 0.8 percent. The OMX Helsinki 25 Index fell 0.6 percent, while the Copenhagen 20 Index declined 0.1 percent.

Clavis Pharma ASA (CLAVIS NO): The Norwegian cancer drug development company signed a $205 million deal with Clovis Oncology for the development and commercialization of anti- cancer agent CP-4126 in Asia and rest of the world. The shares fell 1.8 percent to 38.2 kroner.

DNO International ASA (DNO NO): The Norwegian oil company reported a third-quarter net loss of $146 million. Analysts estimated a loss of $118 million. The shares rose 3.6 percent to 9.11 kroner.

East Capital Explorer AB (ECEX SS): The Swedish investment company reported a third-quarter net income of 28 million euros compared with 41 million euros a year earlier. The shares slipped 1.3 percent to 75.25 kronor.

Kone Oyj (KNEBV FH): The Finnish company that supplies elevators to the London Underground and the Grand Mosque in Mecca was raised to “neutral” from “sell” at UBS AG. The shares fell less than 0.1 percent to 40.11 euros.

Vestas Wind Systems A/S (VWS DC): The world’s largest maker of wind turbines will increase production in the U.S. even after analysts including HSBC Holdings Plc cut forecasts for installations in the region. The shares fell 2.4 percent to 173.5 kroner.

To contact the reporter on this story: Adam Ewing in Stockholm at

To contact the editor responsible for this story: David Merritt at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.